A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Inclusion Criteria

• •1. Subjects must have histologically proven unresectable/ metastatic solid tumors or lymphomas.
• •2. ≥ 18 years old.
• •3. Life expectancy of at least 6 months.
• •4. Eastern Cooperative Oncology Group performance status 0-2.
• •5. Subjects must have at least one measurable lesion ≥ 1 cm as defined by response criteria.
• •6. Subjects must have received at least two frontline therapies, except for patients initially diagnosed with local advanced or metastatic pancreatic cancer or cholangiocarcinoma.
• •7. Subjects must be off prior therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. Subjects with Anti-PD-1 antibody are eligible which must be resistance.
• •8. Adequate organ function.
• •9. Participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.